Toxicity Profile of Commonly Used Anti-Inflammatory Drugs in Geriatrics
Keywords:
Anti-inflammatory agent, Comorbidity, Geriatrics, InflammationAbstract
Background: Anti-inflammatory drugs are commonly used in geriatrics. Geriatrics usually encounter problems of pain and inflammation and are more vulnerable to the toxicity of drugs as compared to young patients. In this review, we aimed to find out the toxic profile of drugs and the pharmacotherapy considerations for geriatric care.
Methods: The electronic databases like Google Scholar, PubMed, ScienceDirect, and different related text books of recent edition were searched using specific keywords for preparing this narrative review. Related experts in the field were also consulted. Papers published in English language were included in the review.
Results: The diseases geriatrics mostly suffered from are osteoarthritis (OA), ankylosing spondylitis, carcinoma, and other degenerative disorders that require anti-inflammatory medicines. Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are mostly used agents for the treatment of inflammation in such population. As the pharmacokinetics of drugs get altered due to alteration in body physiology in geriatrics, the pharmacodynamics also gets affected, and hence toxicity ensues even with normal dose. Depending upon the nature of the drugs, presence of comorbidity, and poly-pharmacy; gastrointestinal, renal, and cardiovascular toxicities occur. Due to this reason, utmost care should be taken for pharmacotherapy practice in geriatrics.
Conclusion: In geriatrics, the anti-inflammatory drugs should be used rationally for the shortest duration possible at the lowest effective dose. The careful evaluation of the beneficial and potential risks of the agents and pharmacovigilance must be considered for pharmacotherapy practice in such populations.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
All articles published in EJMS are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). The author(s) as the copyright holder will retain the ownership of the copyrights without any restrictions for their content under the CC-BY 4.0 license, and allow others to copy, use, print, share, modify, and distribute the content of the article even in commercial purpose as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers. Appropriate attribution can be provided by simply citing the original article.
On behalf of all the authors, the corresponding author is responsible for completing and returning the agreement form to the editorial office. More information about the terms and conditions, privacy policies, and copyrights can be found on the webpage of the Creative Commons license privacy policy. https://creativecommons.org/licenses/by/4.0/